BACKGROUND AND OBJECTIVES: To compare clinically and radiographically, the regenerative potential of a β-tricalcium phosphate bone graft, Cerasorb(®) with and without a bioresorbable type I collagen membrane, BioMend Extend™, in treating periodontal infrabony osseous defects. MATERIALS AND METHODS: A total of 20 sites from 10 patients showing bilateral infrabony defects were selected and selected sites were randomly divided into experimental site A (Cerasorb(®)) and experimental site B (Cerasorb(®) and BioMend Extend™) by using split mouth design. The clinical parameters like plaque index, gingival index, probing pocket depth, clinical attachment level and gingival recession were recorded at baseline, 6 weeks, 3, 6 and 9 months. Radiographic evaluation (Linear CADIA) at 6 and 9 months; and intrasurgical measurements at baseline and 9 months were carried out to evaluate the defect fill, change in alveolar crest height and defect resolution. RESULTS: Significant reduction in all clinical parameters was observed in both the groups. On comparison no statistical significance was observed between the two groups. Radiographically, in site A there was significant defect fill of 78.4 and 97.2% at 6 and 9 months respectively. Whereas in site B reduction was 78.4 and 97.2% at 6 and 9 months respectively. After surgical re-entry, there was significant defect fill of 89.2 and 74% in both groups. INTERPRETATION AND CONCLUSION: Individually both the graft and membrane have shown promising results in the management of periodontal intrabony defects. But the added benefit by combining Cerasorb(®) with BioMend Extend™ was not observed statistically in both clinical radiographic findings.
RCT Entities:
BACKGROUND AND OBJECTIVES: To compare clinically and radiographically, the regenerative potential of a β-tricalcium phosphate bone graft, Cerasorb(®) with and without a bioresorbable type I collagen membrane, BioMend Extend™, in treating periodontal infrabony osseous defects. MATERIALS AND METHODS: A total of 20 sites from 10 patients showing bilateral infrabony defects were selected and selected sites were randomly divided into experimental site A (Cerasorb(®)) and experimental site B (Cerasorb(®) and BioMend Extend™) by using split mouth design. The clinical parameters like plaque index, gingival index, probing pocket depth, clinical attachment level and gingival recession were recorded at baseline, 6 weeks, 3, 6 and 9 months. Radiographic evaluation (Linear CADIA) at 6 and 9 months; and intrasurgical measurements at baseline and 9 months were carried out to evaluate the defect fill, change in alveolar crest height and defect resolution. RESULTS: Significant reduction in all clinical parameters was observed in both the groups. On comparison no statistical significance was observed between the two groups. Radiographically, in site A there was significant defect fill of 78.4 and 97.2% at 6 and 9 months respectively. Whereas in site B reduction was 78.4 and 97.2% at 6 and 9 months respectively. After surgical re-entry, there was significant defect fill of 89.2 and 74% in both groups. INTERPRETATION AND CONCLUSION: Individually both the graft and membrane have shown promising results in the management of periodontal intrabony defects. But the added benefit by combining Cerasorb(®) with BioMend Extend™ was not observed statistically in both clinical radiographic findings.